Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
The Lancet Neurology,  Clinical Article

Farkkila M et al. – Oral lasmiditan seems to be safe and effective in the acute treatment of migraine. Further assessment in larger placebo–controlled and triptan–controlled trials are needed to assess the potential role of lasmiditan in acute migraine therapy.

Methods
  • In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo.
  • Study drug and placebo were supplied in identical numbered tablet packs.
  • The randomisation code was generated by an independent statistician.
  • Patients and investigators were masked to treatment allocation.
  • The primary endpoint was dose response for headache relief (moderate or severe becoming mild or none) at 2 h.
  • The primary analysis was done in the modified intention-to-treat population.

Results
  • Between July 8 2009, and Feb 18, 2010, 512 patients were randomly assigned to treatment, 391 of whom received treatment.
  • 86 patients received placebo (81 included in primary analysis) and 305 received lasmiditan (50 mg n=79, 100 mg n=81, 200 mg n=69, and 400 mg n=68 included in primary analysis).
  • There was a linear association between headache response rate at 2 h and lasmiditan dose (Cochran-Armitage test p<0.0001).
  • Every lasmiditan treatment dose significantly improved headache response at 2 h compared with placebo (lasmiditan 50 mg: difference 17.9%, 95% CI 3.9-32.1, p=0.022; 100 mg: 38.2%, 24.1-52.4, p<0.0001; 200 mg: 28.8%, 9.6-39.9, p=0.0018; 400 mg: 38.7%, 23.9-53.6, p<0.0001).
  • The proportion of patients with treatment-emergent adverse events increased with increasing doses (53/82 [65%], 59/82 [72%], 61/71 [86%], and 59/70 [84%] for lasmiditan 50, 100, 200, and 400 mg, respectively vs 19/86 [22%] for placebo).
  • Most adverse events were mild or moderate in intensity, with 16 of 82 (20%), 23 of 82 (28%), 28 of 71 (39%), and 31 of 70 (44%) of patients on lasmiditan 50, 100, 200, and 400 mg, respectively reporting a severe adverse event compared with five of 86 (6%) on placebo.
  • The most common adverse events were CNS related and included dizziness, fatigue, vertigo, paraesthesia, and somnolence.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

1 Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau) World Journal of Urology, November 3, 2014    Clinical Article

2 Impact of the 2012 United States preventive services task force statement on prostate-specific antigen screening: Analysis of urologic and primary care practices Urology, November 17, 2014    Clinical Article

3 Dairy products, calcium, and prostate cancer risk: A systematic review and meta-analysis of cohort studies American Journal of Clinical Nutrition, November 26, 2014    Clinical Article

4 Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective Urologic Oncology: Seminars and Original Investigations, November 10, 2014    Clinical Article

5 Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy Urologic Oncology: Seminars and Original Investigations, November 24, 2014    Clinical Article

6 Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women’s Health Initiative Memory Study Journal of the Academy of Nutrition and Dietetics, November 12, 2014    Clinical Article

7 Association of fat density with subclinical atherosclerosis Full Text Journal of the American Heart Association, September 19, 2014    Free full text

8 Acupuncture and immune function in chronic prostatitis/chronic pelvic pain syndrome: a randomized, controlled study Complementary Therapies in Medicine, October 31, 2014    Clinical Article

9 Rapid and durable protection against Ebola virus with new vaccine regimens Full Text National Institute of Allergy and Infectious Disease - News, September 9, 2014    Free full text

10 Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride The Journal of Sexual Medicine, November 7, 2014    Clinical Article

11 An European multicenter randomized noninferiority trial comparing 180-W greenlight-XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-months results of the goliath-study The Journal of Urology, November 4, 2014    Clinical Article

12 State-of-the-art treatment of hypertension: Established and new drugs Full Text European Heart Journal, November 14, 2013    Free full text    Clinical Article

13 A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients International Journal of Impotence Research: The Journal of Sexual Medicine, August 12, 2014    Clinical Article

14 Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening The Journal of Urology, November 11, 2014    Clinical Article

15 Effect of surgical margin status after radical prostatectomy on health-related quality of life and illness perception in patients with prostate cancer Urologic Oncology: Seminars and Original Investigations, November 25, 2014    Clinical Article

16 Carbohydrate intake, glycemic index and prostate cancer risk The Prostate, November 26, 2014    Clinical Article

17 Depression, anxiety, antidepressant use, and cardiovascular disease among Hispanic men and women of different national backgrounds: results from the Hispanic Community Health Study/Study of Latinos Annals of Epidemiology , November 14, 2014    Clinical Article

18 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 21, 2014    Evidence Based Medicine    Clinical Article

19 A clinical randomized controlled trial of music therapy and progressive muscle relaxation training in female breast cancer patients after radical mastectomy: Results on depression, anxiety and length of hospital stay European Journal of Oncology Nursing , November 5, 2014    Clinical Article

20 Comparison of cognitive behavioral therapy and supportive psychotherapy for the treatment of depression following traumatic brain injury: a randomized controlled trial Journal of Head Trauma Rehabilitation, November 20, 2014    Clinical Article

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore